GlassScriptPhysician profile
Timothy M Miller
NPI 1255356671
$82,466.29
in general payments reported to CMS, 2019-2025
10 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,075 · 2021: $5,474 · 2022: $19K · 2023: $44K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,640 · Travel and Lodging: $734 · Food and Beverage: $38.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,780.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,640.00 |
| Travel and Lodging | $733.85 |
| Food and Beverage | $38.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $74,153.63 | 2020-2025 | Qalsody |
| Biomarin Pharmaceutical INC. | $5,412.66 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $1,750.00 | 2021 | |
| Ionis Pharmaceuticals, INC. | $650.00 | 2025 | |
| Genentech, INC. | $500.00 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.